PDLI - PDLバイオファ―マ (PDL BioPharma Inc.)

PDLIのニュース

   PDL BioPharma reports Q3 results (NASDAQ:PDLI)  2020/11/11 10:38:27 Seeking Alpha
PDL BioPharma (NASDAQ:PDLI): Q3 GAAP EPS of -$0.64. Revenue of $7.1M (-12.3% Y/Y) Press Release
   PDL BioPharma (NASDAQ:PDLI) Shares Down 5.2%  2020/10/21 10:36:45 Zolmax News
PDL BioPharma, Inc. (NASDAQ:PDLI)’s share price traded down 5.2% during trading on Monday . The company traded as low as $2.20 and last traded at $2.20. 755,649 shares traded hands during mid-day trading, a decline of 36% from the average session volume of 1,182,237 shares. The stock had previously closed at $2.32. A number of […]
   Reviewing PDL BioPharma (NASDAQ:PDLI) & Acorda Therapeutics (NASDAQ:ACOR)  2020/10/20 10:04:42 Zolmax News
PDL BioPharma (NASDAQ:PDLI) and Acorda Therapeutics (NASDAQ:ACOR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations. Earnings & Valuation This table compares PDL BioPharma and Acorda Therapeutics’ revenue, earnings per share […]
   PDL BioPharma Completes Divestiture of the Noden Pharmaceutical Business to Stanley Capital  2020/09/09 12:30:00 PR Newswire
INCLINE VILLAGE, Nev., Sept. 9, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the closing of the sale of its wholly owned subsidiaries Noden Pharma DAC and Noden Pharma USA (collectively "Noden") to Stanley Capital. The total value of the…
   PDL BioPharma Announces Sale of Kybella®, Zalviso® and Coflex® Royalties to SWK Holdings Corporation  2020/08/31 13:00:00 PR Newswire
INCLINE VILLAGE, Nev., Aug. 31, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the signing and closing of a definitive agreement for the sale of three royalty interests for Kybella®, Zalviso®, and Coflex® (collectively the "Royalties") to SWK…
   PDL BioPharma (NASDAQ:PDLI) Shares Down 5.2%  2020/10/21 10:36:45 Zolmax News
PDL BioPharma, Inc. (NASDAQ:PDLI)’s share price traded down 5.2% during trading on Monday . The company traded as low as $2.20 and last traded at $2.20. 755,649 shares traded hands during mid-day trading, a decline of 36% from the average session volume of 1,182,237 shares. The stock had previously closed at $2.32. A number of […]
   Reviewing PDL BioPharma (NASDAQ:PDLI) & Acorda Therapeutics (NASDAQ:ACOR)  2020/10/20 10:04:42 Zolmax News
PDL BioPharma (NASDAQ:PDLI) and Acorda Therapeutics (NASDAQ:ACOR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations. Earnings & Valuation This table compares PDL BioPharma and Acorda Therapeutics’ revenue, earnings per share […]
   PDL BioPharma Completes Divestiture of the Noden Pharmaceutical Business to Stanley Capital  2020/09/09 12:30:00 PR Newswire
INCLINE VILLAGE, Nev., Sept. 9, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the closing of the sale of its wholly owned subsidiaries Noden Pharma DAC and Noden Pharma USA (collectively "Noden") to Stanley Capital. The total value of the…
   PDL BioPharma Announces Sale of Kybella®, Zalviso® and Coflex® Royalties to SWK Holdings Corporation  2020/08/31 13:00:00 PR Newswire
INCLINE VILLAGE, Nev., Aug. 31, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the signing and closing of a definitive agreement for the sale of three royalty interests for Kybella®, Zalviso®, and Coflex® (collectively the "Royalties") to SWK…
   PDL BioPharma Announces Offer to Purchase Convertible Notes Due 2021 and 2024  2020/08/28 12:30:00 PR Newswire
INCLINE VILLAGE, Nev., Aug. 28, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that holders of its 2.75% Convertible Senior Notes due in December 2021 (the "2021 Notes") and in December 2024 (the "2024 Notes" and together with the 2021…
   PDL BioPharma (NASDAQ:PDLI) Shares Down 5.2%  2020/10/21 10:36:45 Zolmax News
PDL BioPharma, Inc. (NASDAQ:PDLI)’s share price traded down 5.2% during trading on Monday . The company traded as low as $2.20 and last traded at $2.20. 755,649 shares traded hands during mid-day trading, a decline of 36% from the average session volume of 1,182,237 shares. The stock had previously closed at $2.32. A number of […]
   Reviewing PDL BioPharma (NASDAQ:PDLI) & Acorda Therapeutics (NASDAQ:ACOR)  2020/10/20 10:04:42 Zolmax News
PDL BioPharma (NASDAQ:PDLI) and Acorda Therapeutics (NASDAQ:ACOR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations. Earnings & Valuation This table compares PDL BioPharma and Acorda Therapeutics’ revenue, earnings per share […]
   PDL BioPharma Completes Divestiture of the Noden Pharmaceutical Business to Stanley Capital  2020/09/09 12:30:00 PR Newswire
INCLINE VILLAGE, Nev., Sept. 9, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the closing of the sale of its wholly owned subsidiaries Noden Pharma DAC and Noden Pharma USA (collectively "Noden") to Stanley Capital. The total value of the…
   PDL BioPharma Announces Sale of Kybella®, Zalviso® and Coflex® Royalties to SWK Holdings Corporation  2020/08/31 13:00:00 PR Newswire
INCLINE VILLAGE, Nev., Aug. 31, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the signing and closing of a definitive agreement for the sale of three royalty interests for Kybella®, Zalviso®, and Coflex® (collectively the "Royalties") to SWK…
   PDL BioPharma Announces Offer to Purchase Convertible Notes Due 2021 and 2024  2020/08/28 12:30:00 PR Newswire
INCLINE VILLAGE, Nev., Aug. 28, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that holders of its 2.75% Convertible Senior Notes due in December 2021 (the "2021 Notes") and in December 2024 (the "2024 Notes" and together with the 2021…

calendar